BIONIME CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.9 TWD | -1.85% |
|
-1.15% | -7.89% |
| Mar. 15 | Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 14 | Bionime Corporation Announces Dividend for the Year Ended December 31, 2023 | CI |
| Sales 2024 * | 2.1B 64.52M | Sales 2025 * | - | Capitalization | 4.2B 129M |
|---|---|---|---|---|---|
| Net income 2024 * | 72M 2.21M | Net income 2025 * | - | EV / Sales 2024 * | 2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
57.9
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.85% | ||
| 1 week | -1.15% | ||
| Current month | -2.27% | ||
| 1 month | -2.27% | ||
| 3 months | -0.86% | ||
| 6 months | -13.22% | ||
| Current year | -7.89% |
1 week
68.30
70.50
1 month
68.0070.80
Current year
67.2076.60
1 year
67.2090.10
3 years
65.3097.80
5 years
47.6597.80
10 years
38.1097.80
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Mu Huang
CEO | Chief Executive Officer | - | 03-04-13 |
Hui Chen Chen
DFI | Director of Finance/CFO | - | 17-11-05 |
Zhi Long Yeh
CTO | Chief Tech/Sci/R&D Officer | - | 18-11-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Mu Huang
CEO | Chief Executive Officer | - | 03-04-13 |
| Director/Board Member | - | 07-10-16 | |
Chung Kai Tai
BRD | Director/Board Member | - | 07-05-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 68.9 | -1.85% | 68,042 |
| 24-04-18 | 70.2 | +1.74% | 37,054 |
| 24-04-17 | 69 | +0.15% | 37,010 |
| 24-04-16 | 68.9 | -0.29% | 59,104 |
| 24-04-15 | 69.1 | -0.86% | 39,107 |
End-of-day quote Taiwan S.E., April 18, 2024
More quotes
Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
68.9
TWD
Average target price
80
TWD
Spread / Average Target
+16.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.89% | 129M | |
| -1.04% | 12.55B | |
| -17.29% | 7.02B | |
| -2.21% | 5.19B | |
| +2.92% | 4.37B | |
| -4.79% | 4.35B | |
| -50.07% | 3.33B | |
| +7.65% | 2.62B | |
| -15.92% | 2.03B | |
| -3.34% | 1.67B |
- Stock Market
- Equities
- 4737 Stock
